Kv1.5 potassium channel is an efficacious and safe therapeutic target for the treatment of atrial fibrillation (AF), the most common arrhythmia that threatens human. Herein, by modifying the hit compound 7k from an in-house database, 48 derivatives were synthesized for the assay of their Kv1.5 inhibitory effects by whole cell patch clamp technique. Six compounds which showed better potency than the positive compound dronedarone were selected for the next evaluation of their drug-like properties. Compound 8 exhibited balanced solubility and permeability. It also showed acceptable pharmacodynamics profile with very low acute toxicity. Taking all these data into account, compound 8 can serve as a promising lead for the development of novel therapeutic agent for the treatment of AF.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejmech.2014.03.075 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sigma-1 receptor modulation fine-tunes K1.5 channels and impacts pulmonary vascular function.
Pharmacol Res
March 2023
Department of Pharmacology and Toxicology, School of Medicine, University Complutense of Madrid, Madrid, Spain; Ciber Enfermedades Respiratorias (CIBERES), Spain; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain. Electronic address:
K1.5 channels are key players in the regulation of vascular tone and atrial excitability and their impairment is associated with cardiovascular diseases including pulmonary arterial hypertension (PAH) and atrial fibrillation (AF). Unfortunately, pharmacological strategies to improve K1.
View Article and Find Full Text PDFPseudosaccharin amines as potent and selective KV1.5 blockers.
Bioorg Med Chem Lett
November 2015
Bristol-Myers Squibb Research and Development, PO Box 5400, Princeton, NJ 08534-5400, USA.
Phenethyl aminoheterocycles like compound 1 were known to be potent I(Kur) blockers although they lacked potency in vivo. Modification of the heterocycle led to the design and synthesis of pseudosaccharin amines. Compounds such as 14, 17d and 21c were found to be potent K(V)1.
View Article and Find Full Text PDFDesign, synthesis and evaluation of phenethylaminoheterocycles as K(v)1.5 inhibitors.
Bioorg Med Chem Lett
July 2014
Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, PO Box 5400, Princeton, NJ 08534-5400, USA.
Phenethylaminoheterocycles have been prepared and assayed for inhibition of the Kv1.5 potassium ion channel as a potential approach to the treatment of atrial fibrillation. A diverse set of heterocycles were identified as potent Kv1.
View Article and Find Full Text PDFMultiple mRNA isoforms encoding the mouse cardiac Kv1-5 delayed rectifier K+ channel.
J Biol Chem
November 1993
Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France.
Article Synopsis
- Researchers cloned the mouse Kv1-5 K+ channel cDNA from heart tissue, finding high expression in the heart and lower levels in the brain and thymus.
- Two isoforms were identified: a longer one with 602 amino acids and a shorter variant (Kv1-5 delta 5') missing the first 200 amino acids due to splicing.
- Both isoforms were present in various mouse tissues, with the longer form being more common; the carboxyl-terminal truncated form (Kv1-5 delta 3') was found to be nonfunctional but inhibited the longer isoform's expression.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!